A systematic review and meta-analysis of health-related quality of life values derived from EQ-5D-5L in psoriatic patients

Purposes: To synthesise the health-related quality of life (HRQoL) values derived from the EQ-5D-5L in psoriatic patients. Methods: A literature search was conducted in PubMed, Embase, Cochrane Library, and Trip databases on 27 January 2023, reporting HRQoL values derived from EQ-5D-5L in psoriatic patients. Meta-analysis was performed to estimate HRQoL in psoriatic patients, with subgroup analyses conducted on Asian versus non- Asian populations, and in plaque psoriasis and psoriatic arthritis patients. Results: Eighteen studies with 7,015 patients were included in this study. The pooled EQ-5D-5L value in psoriatic patients was 0.73 (95% CI: 0.68-0.79; I²=99.4%). The value was not significantly different in the Asian versus non-Asian subgroup, being 0.83 (95% CI: 0.76-0.91) and 0.76 (95% CI: 0.72-0.80) respectively. The value in the plaque psoriasis subgroup was 0.83 (95% CI: 0.78-0.88), which was higher than 0.68 (95% CI: 0.64-0.72) in psoriatic arthritis patients. Conclusions: This study provides a comprehensive and updated estimate of HRQoL value derived from EQ-5D-5L in psoriatic patients. The pooled value did not differ in the Asian versus non-Asian population. Psoriatic arthritis patients had a lower value compared to plaque psoriasis patients. This study will be useful for future economic evaluations of psoriasis treatments.